Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MLYCD | O95822 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4344014 | 0.92 | MAPK14 (0.71) | MAPK14LMNAHSP90AA1MLYCD | |
| SCHEMBL4328387 | 0.92 | MAPK14 (0.74) | MAPK14LMNAMAPK9MAPK10MAPK11 | |
| SCHEMBL4337525 | 0.91 | MAPK14 (0.75) | MAPK14MAPK9MAPK10MAPK11MLYCD | |
| SCHEMBL4330141 | 0.89 | MAPK14 (0.76) | MAPK14LMNANPC1MLYCD | |
| SCHEMBL4469515 | 0.89 | MAPK14 (0.76) | MAPK14LMNANPC1MLYCD | |
| SCHEMBL4332724 | 0.89 | MAPK14 (0.78) | MAPK14LMNANPC1MLYCD | |
| SCHEMBL27765835 | 0.87 | MAPK14 (0.73) | MAPK14LMNAMAPK9MAPK10MAPK11 | |
| SCHEMBL27744981 | 0.87 | MAPK14 (0.68) | MAPK14LMNAMAPK9MAPK10MAPK11 | |
| SCHEMBL4463937 | 0.87 | MAPK14 (0.76) | MAPK14LMNAMAPK9MAPK10MAPK11 | |
| SCHEMBL4341935 | 0.87 | MAPK14 (0.75) | MAPK14LMNAMLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2036905-B1 | PYRIDYLISOXAZOLE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2012-12-12 | — | — | EP | disclosed |
| US-8207203-B2 | Pyridylisoxazole derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20090306145-A1 | Pyridylisoxazole Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| CN-101472921-A | Pyridylisoxazole derivative | ASKA PHARM CO LTD (JP) | 2009-07-01 | — | — | CN | disclosed |
| EP-2036905-A1 | PYRIDYLISOXAZOLE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306145-A1 | Pyridylisoxazole Derivatives | CNKSR1, MAPK1, MAPK3 | MAPK14 43/4885LMNA 4792/4885MAPK9 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.